Pluristem Therapeutics, Inc. (PSTI) Moves Ahead with PLX-PAD Clinical Trials after Positive Feedback from FDA and EMA
Pluristem, a leading developer of placenta-based cell therapies for treating local and systemic inflammatory diseases, feels that positive feedback received from both the FDA (Food and Drug Administration) and the EMA (European Medical Agencies) regarding its PLX-PAD product for treating PAD (Peripheral Artery Disease), a chronic disease that progressively restricts blood flow in the limbs, clears the way for further clinical studies with its PLX-PAD cells. The company is now on track to proceed to a Phase II/III trial for CLI (Critical Limb Ischemia) and a Phase II trial for IC (Intermittent Claudication). The company recently announced the successful completion…